Efficacy and Safety of AJU-C52 in Essential Hypertension Patients

Launched by AJU PHARM CO., LTD. · May 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called AJU-C52 for patients with essential hypertension, which is high blood pressure that isn’t caused by another health issue. The purpose of the trial is to see if AJU-C52 is effective and safe compared to another treatment called C52R1M for patients who are not able to manage their blood pressure well with their current medication. The trial is currently recruiting participants who are adults aged 19 and older and have been diagnosed with essential hypertension. They must meet specific blood pressure criteria to qualify.

If you choose to participate, you will be randomly assigned to receive either AJU-C52 or the comparison treatment. Throughout the study, you will have regular check-ups to monitor your blood pressure and overall health. It's important to note that certain individuals, such as those with other serious health conditions or a history of certain types of cancer, may not be eligible to join the trial. This study aims to improve treatment options for people with high blood pressure, so your involvement could help others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged ≤19 years.
• • Those who voluntarily signed the informed consent to participate in this study.
• • A patient diagnosed with essential hypertension or Patients taking hypertension medication
• • Those who are eligible for adequate blood pressure criteria during screening tests: Naïve patient-160 mmHg≤MSSBP\<200 mmHg and MSDBP\<110 mmHg/Patients taking hypertension medication-140 mmHg≤MSSBP\<200 mmHg and MSDBP\<110 mmHg
• Exclusion Criteria:
• • At the screening visit (Visit 1), patients had 3 blood pressure measurements in the arm with the higher average MSSBP, those whose maximum and minimum blood pressure differences are MSSBP 20 mmHg and MSDBP 10 mmHg
• • Secondary hypertension patients or those with a history of suspected secondary hypertension
• • Cardiovascular/cerebrovascular disease
• • Those with a history of malignant tumor within 5 years